Skip to main content
. 2011 Feb 2;6:129–139. doi: 10.2147/COPD.S8092

Table 2.

Summary of effect sizes from outcomes reported in the included trials

Comparison/outcome WMD*/RR** 95% CI P value No. of studies in outcome (participants)
Respimat versus Handihaler
Trough FEV1 (L) 0.01* 0.00 to 0.03 0.14 3 (693)
Trough FVC (L) 0.001* −0.04 to 0.03 0.88 3 (693)
Peak FEV1 (L) 0.01* 0.00 to 0.03 0.08 2 (642)
Peak FVC (L) 0.01* −0.02 to 0.04 0.55 2 (642)
Morning PEFR (L/min) 5.06* −0.69 to 10.72 0.08 2 (425)
Evening PEFR (L/min) 4.39* −1.54 to 10.31 0.15 2 (425)
Adverse events
  Exacerbations 0.94* 0.58 to 1.54 0.81 3 (715)
  Dry mouth 1.57* 0.62 to 3.97 0.34 3 (715)
  Diarrhea 0.33* 0.04 to 3.17 0.34 1 (294)
  Nasophryngitis 1.42* 0.81 to 2.46 0.22 2 (664)
Respimat versus CFC-MDI
Adverse events
  Exacerbations 1.20 0.95 to 1.51 0.12 2 (1421)
  Nasophryngitis 1.21 0.62 to 2.38 0.58 1 (977)

Notes:

*

WMD;

**

RR.

Abbreviations: CFC-MDI, chlorofluorocarbon metered-dose inhaler; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEFR, peak expiratory flow rate; RR, relative risk; WMD, weighted mean difference.